Send to

Choose Destination
Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Author information

Centro Ricerca e Innovazione delle Malattie Mieloproliferative (CRIMM), Azienda Ospedaliera-Universitaria Careggi, Firenze, Italy.
Department of Experimental and Clinical Medicine, DENOTHE Centre, University of Florence, Florence, Italy.
Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Division of Hematology, Department of Specialistic Medicine, Ospedale Azienda Socio Sanitaria Territoriale (ASST)-Sette Laghi, Varese, Italy.
Department of Experimental and Clinical Medicine, University of Insubria, Varese, Italy.
GenOMec, University of Siena, Siena, Italy.
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Oncology-Hematology Università degli Studi di Milano, Milan, Italy; and.
FROM Research Foundation, Bergamo, Italy.


The 2016 revision of the World Health Organization (WHO) classification of myeloproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF): prefibrotic/early (pre-PMF) and overt fibrotic (overt PMF) phase. In this work, we studied the clinical and molecular features of patients belonging to these categories of PMF. The diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to modern criteria; clinical information and annotation of somatic mutations in both driver and selected nondriver myeloid genes were available for all patients. Compared with pre-PMF, overt PMF was enriched in patients with anemia, thrombocytopenia, leukopenia, higher blast count, symptoms, large splenomegaly, and unfavorable karyotype. The different types of driver mutations were similarly distributed between the 2 categories, whereas selected mutations comprising the high mutation risk (HMR) category (any mutations in ASXL1, SRSF2, IDH1/2, EZH2) were more represented in overt PMF. More patients with overt PMF were in higher International Prognostic Scoring System risk categories at diagnosis, and the frequency increased during follow-up, suggesting greater propensity to disease progression compared with pre-PMF. Median survival was significantly shortened in overt PMF (7.2 vs 17.6 years), with triple negativity for driver mutations and presence of HMR mutations representing independent predictors of unfavorable outcome. The findings of this "real-life" study indicate that adherence to 2016 WHO criteria allows for identification of 2 distinct categories of patients with PMF where increased grades of fibrosis are associated with more pronounced disease manifestations, adverse mutation profile, and worse outcome, overall suggesting they might represent a phenotypic continuum.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center